Xylate Solution for Infusion 200 ml, Neurocytin Solution for Infusion 100 ml, Arginine Hydrochloride Solution for Infusion 84 mg/ml 50 ml

The Communal Non-Profit Enterprise "Lviv Regional Infectious Clinical Hospital" of the Lviv Regional Council is seeking to procure several pharmaceutical products: Xylate solution for infusion (200 ml), Neurocytin solution for infusion (100 ml), and Arginine Hydrochloride solution for infusion (84 mg/ml, 50 ml). These items fall under the general classification of miscellaneous medicinal preparations, identified by CPV code 33690000-3. Xylate is often used for its hepatoprotective and detoxifying properties, Neurocytin may be used for neurological conditions, and Arginine Hydrochloride is an amino acid supplement used in various medical contexts, including liver support and metabolic disorders. The tender aims to secure a reliable supply of these essential medications to support patient treatment within the hospital. Bidders are expected to provide products that meet all quality, safety, and efficacy standards. The full tender documentation will contain detailed specifications regarding quantities, packaging, delivery schedules, and other procurement terms. The Lviv Regional Infectious Clinical Hospital requires these medications to ensure comprehensive patient care.

This is a supplies contract in the health and medical services sector, with a focus on Hospitals and Pharmaceuticals. Located in Ukraine, Europe, this opportunity is open to firms and consortiums, with an estimated budget of UAH 1.0 million.

Published through ProZorro Ukraine, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.